Botanix’s product pipeline includes three advanced clinical programs which are leveraging synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Botanix also has an active discovery chemistry program to identify, synthesise, and test novel chemical entities that are structurally related to naturally occurring cannabinoids. In addition, Botanix has an exclusive license to use a proprietary drug delivery system called Permetrex, for direct skin delivery of pharmaceuticals.
| PRODUCT | INDICATION | PHASE 1 | PHASE 1B | PHASE 2 | PHASE 3 | STATUS |
|---|---|---|---|---|---|---|
| BTX 1503 Gel | Moderate to severe acne |
|
Successful End of Phase 2 Meeting with FDA | |||
| BTX 1702 Solution | Rosacea |
|
Phase 2b study | |||
| BTX 1801 Ointment | Antimicrobial |
|
Phase 2a study | |||